COVID-19 Impact on Cardiology Disease " target="_blank">COVID-19 Impact on Cardiology Disease in Healthcare Industry
OVERVIEW
A recently recognized coronavirus SARS-CoV-2 has caused an overall pandemic of respiratory ailment called COVID-19. The virus first appeared in Wuhan, a city of China in December 2019. The patients suffering from COVID-19 are treated very carefully with all the precautions because this disease spreads fast through physical contact. For COVID-19, no vaccine has been discovered yet; precautions include regular hand-wash and maintaining social distance. There are theoretical risks that a viral infection can cause the rupture of atherosclerotic plaques (fatty deposits) in the coronary arteries leading to acute coronary syndrome based on the inflammatory effects of the virus (heart attack). It is possible for someone to catch the infection. People with underlying heart problems, however, may be more likely than others to display signs of the infection or to have a more serious infection.

IMPACT ON PRICE
Due to COVID-19, the market is disturbed to a very big level. But as the patients who are already suffering from heart diseases and lung diseases are more prone to COVID-19, so overcoming these situations, the older patients are treated very seriously. So the demand is increasing day-by-day for different cardiac drugs that is increasing the competition in the manufacturers to produce more and good quality of cardiac drugs so that they can meet the expectation of doctors and patients. The latest data have shown that the price has decreased related to the data available before COVID-19 due to a rise in demand for cardiology devices and cardiology drugs. Significant quantities of drugs and devices are produced by large manufacturing firms but with a top notch consistency. Read in detail...